Opioid use disorder treatment and the role of New Jersey Medicaid policy changes: perspectives of office-based buprenorphine providers

References

• Patton M. Qualitative research & evaluation methods [Internet]. SAGE Publications Inc. 2020 [accessed 2020 Aug 11]. https://us.sagepub.com/en-us/nam/qualitative-research-evaluation-methods/book232962.
   Google Scholar
• US Centers for Disease Control & Prevention. Opioid data analysis and resources [Internet]. 2021 [accessed 2022 May 12]. https://www.cdc.gov/opioids/data/analysis-resources.html.
   Google Scholar
• Sofuoglu M, DeVito EE, Carroll KM. Pharmacological and behavioral treatment of opioid use disorder. Psychiatr Res Clin Pract. 2019;1:4–15. doi:10.1176/appi.prcp.20180006.
   Google Scholar
• Olfson M, Zhang V, Schoenbaum M, King M. Buprenorphine treatment by primary care providers, psychiatrists, addiction specialists, and others: trends in buprenorphine treatment by prescriber specialty - primary care providers, psychiatrists, and addiction medicine specialists. Health Aff. 2020;39:984–92. doi:10.1377/hlthaff.2019.01622.
   Web of Science ®Google Scholar
• Chang ET, Oberman RS, Cohen AN, Taylor SL, Gumm E, Mardian AS, Toy S, Revote A, Lewkowitz B, Yano EM, et al. Increasing access to medications for opioid use disorder and complementary and integrative health services in primary care. J Gen Intern Med. 2020;35:918–26. doi:10.1007/s11606-020-06255-6.
   PubMed Web of Science ®Google Scholar
• Oros SM, Christon LM, Barth KS, Berini CR, Padgett BL, Diaz VA. Facilitators and barriers to utilization of medications for opioid use disorder in primary care in South Carolina. Int J Psychiatry Med. 2021;56:14–39. doi:10.1177/0091217420946240.
   PubMed Web of Science ®Google Scholar
• Russell HA, Sanders M, Meyer JKV, Loomis E, Mullaney T, Fiscella K. Increasing access to medications for opioid use disorder in primary care: removing the training requirement may not be enough. J Am Board Fam Med. 2021;34:1212–15. doi:10.3122/jabfm.2021.06.210209.
   PubMed Web of Science ®Google Scholar
• Andrilla CHA, Moore TE, Patterson DG. Overcoming barriers to prescribing buprenorphine for the treatment of opioid use disorder: recommendations from rural physicians. J Rural Health. 2019;35:113–21. doi:10.1111/jrh.12328.
   PubMed Web of Science ®Google Scholar
• Dickson-Gomez J, Spector A, Weeks M, Galletly C, McDonald M, Green Montaque HD. “You’re not supposed to be on it forever”: Medications to treat opioid use disorder (MOUD) related stigma among drug treatment providers and people who use opioids. Subst abuse. 2022;16:117822182211038. doi:10.1177/11782218221103859.
   Web of Science ®Google Scholar
• Vitale JPL. c.28. 2017. 2017. https://www.njleg.state.nj.us/legislative-roster/175/senator-vitale
   Google Scholar
• Treitler P, Nowels M, Samples H, Crystal S. Buprenorphine utilization and prescribing among new jersey medicaid beneficiaries after adoption of initiatives designed to improve treatment access. JAMA Network Open. 2023;6:e2312030. doi:10.1001/jamanetworkopen.2023.12030.
   PubMed Web of Science ®Google Scholar
• Andrews CM, Abraham AJ, Grogan CM, Westlake MA, Pollack HA, Friedmann PD. Impact of medicaid restrictions on availability of buprenorphine in addiction treatment programs. Am J Public Health. 2019;109:434–36. doi:10.2105/AJPH.2018.304856.
   PubMed Web of Science ®Google Scholar
• Mark TL, Parish WJ, Zarkin GA. Association of formulary prior authorization policies with buprenorphine-naloxone prescriptions and hospital and emergency department use among medicare beneficiaries. JAMA Network Open. 2020;3:e203132. doi:10.1001/jamanetworkopen.2020.3132.
   PubMed Web of Science ®Google Scholar
• Puckett HM, Bossaller JS, Sheets LR. The impact of project ECHO on physician preparedness to treat opioid use disorder: a systematic review. Addict Sci Clin Pract. 2021;16:6. doi:10.1186/s13722-021-00215-z.
   PubMed Web of Science ®Google Scholar
• Kaplan-Dobbs M, Kattan JA, Tuazon E, Jimenez C, Saleh S, Kunins HV. Increasing access to buprenorphine in safety-net primary care clinics: The New York City buprenorphine nurse care manager initiative. Am J Public Health. 2021;111:215–18. doi:10.2105/AJPH.2020.306000.
   PubMed Web of Science ®Google Scholar
• Madden EF, Prevedel S, Light T, Sulzer SH. Intervention stigma toward medications for opioid use disorder: a systematic review. Subst Use Misuse. 2021;56:2181–201. doi:10.1080/10826084.2021.1975749.
   PubMed Web of Science ®Google Scholar
• Cunningham P, Pierre-Louis S, Britton E, Farzana Urmi A, Barnes A. Addiction and recovery treatment services: evaluation report for state fiscal years 2019 and 2020 [Internet]. Virginia Commonwealth University, School of Medicine; 2022. https://hbp.vcu.edu/policy-briefs/arts-policy-briefs/.
   Google Scholar
• Horizon NJ Health. Find Horizon NJ Health Doctors [Internet]. Horizon NJ Health. 2022 [accessed 2022 May 19]. https://www.horizonnjhealth.com/findadoctor.
   Google Scholar
• SUBLOCADE. Find a buprenorphine treatment provider [Internet]. [accessed 2022 May 19]. https://www.sublocade.com/buprenorphine-treatment-provider.
   Google Scholar
• Hennink M, Kaiser BN. Sample sizes for saturation in qualitative research: A systematic review of empirical tests. Social Sci Med. 2022;292:114523. doi:10.1016/j.socscimed.2021.114523.
   PubMed Web of Science ®Google Scholar
• Damschroder LJ, Reardon CM, Widerquist MAO, Lowery J. The updated consolidated framework for implementation research based on user feedback. Implement Sci. 2022;17:75. doi:10.1186/s13012-022-01245-0.
   PubMed Web of Science ®Google Scholar
• Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009;4:50. doi:10.1186/1748-5908-4-50.
   PubMed Web of Science ®Google Scholar
• Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Am J Public Health. 1999;89:1322–27. doi:10.2105/AJPH.89.9.1322.
   PubMed Web of Science ®Google Scholar
• Miles MB, Huberman AM, Saldaña J. Qualitative data analysis: a methods sourcebook. 3rd ed. Thousand Oaks, California SAGE Publications, Inc. 2014.
   Google Scholar
• Madden EF. Intervention stigma: How medication-assisted treatment marginalizes patients and providers. Social Sci Med. 2019;232:324–31. doi:10.1016/j.socscimed.2019.05.027.
   PubMed Web of Science ®Google Scholar
• Haffajee RL, Andraka-Christou B, Attermann J, Cupito A, Buche J, Beck AJ. A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder. Subst Abuse Treat Prev Policy. 2020;15:69. doi:10.1186/s13011-020-00312-3.
   PubMed Web of Science ®Google Scholar
• Mackey K, Veazie S, Anderson J, Bourne D, Peterson K. Barriers and facilitators to the use of medications for opioid use disorder: a rapid review. J Gen Intern Med. 2020;35:954–63. doi:10.1007/s11606-020-06257-4.
   PubMed Web of Science ®Google Scholar
• Lanham HJ, Papac J, Olmos DI, Heydemann EL, Simonetti N, Schmidt S, Potter JS. Survey of barriers and facilitators to prescribing buprenorphine and clinician perceptions on the drug addiction treatment act of 2000 waiver. JAMA Netw Open. 2022;5:e2212419. doi:10.1001/jamanetworkopen.2022.12419.
   PubMed Web of Science ®Google Scholar
• Burns RM, Pacula RL, Bauhoff S, Gordon AJ, Hendrikson H, Leslie DL, Stein BD. Policies related to opioid agonist therapy for opioid use disorders: The evolution of state policies from 2004 to 2013. Subst Abus. 2016;37:63–69. doi:10.1080/08897077.2015.1080208.
   PubMed Web of Science ®Google Scholar
• Weber E, Gupta A. State medicaid programs should follow the “medicare model” remove prior authorization requirements for buprenorphine and other medications to treat opioid use disorders [Internet]. Legal Action Center; 2019 Jul [accessed 2022 May 27]. https://www.lac.org/resource/state-medicaid-programs-should-follow-the-medicare-model-remove-prior-authorization-requirements-for-buprenorphine-and-other-medications-to-treat-opioid-use-disorders.
   Google Scholar
• Hill LG, Loera LJ, Evoy KE, Renfro ML, Torrez SB, Zagorski CM, Perez JC, Jones SM, Reveles KR. Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA. Addiction. 2021;116:1505–11. doi:10.1111/add.15314.
   PubMed Web of Science ®Google Scholar
• Ostrach B, Carpenter D, Cote LP. DEA disconnect leads to buprenorphine bottlenecks. J Addict Med. 2021:272–75. doi:10.1097/ADM.0000000000000762.
   PubMed Web of Science ®Google Scholar
• Kazerouni NJ, Irwin AN, Levander XA, Geddes J, Johnston K, Gostanian CJ, Mayfield BS, Montgomery BT, Graalum DC, Hartung DM. Pharmacy-related buprenorphine access barriers: an audit of pharmacies in counties with a high opioid overdose burden. Drug Alcohol Depen. 2021;224:108729. doi:10.1016/j.drugalcdep.2021.108729.
   PubMed Web of Science ®Google Scholar
• Cooper HL, Cloud DH, Freeman PR, Fadanelli M, Green T, Van Meter C, Beane S, Ibragimov U, Young AM. Buprenorphine dispensing in an epicenter of the U.S. opioid epidemic: a case study of the rural risk environment in Appalachian Kentucky. Int J Drug Policy. 2020;85:102701. doi:10.1016/j.drugpo.2020.102701.
   PubMed Web of Science ®Google Scholar
• Dutra L, Stathopoulou G, Basden SL, Leyro TM, Powers MB, Otto MW. A meta-analytic review of psychosocial interventions for substance use disorders. AJP. 2008;165:179–87. doi:10.1176/appi.ajp.2007.06111851.
   Web of Science ®Google Scholar
• Dugosh K, Abraham A, Seymour B, McLoyd K, Chalk M, Festinger D. A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction. J Addict Med. 2016;10:93–103. doi:10.1097/ADM.0000000000000193.
   PubMed Web of Science ®Google Scholar
• Rice D, Corace K, Wolfe D, Esmaeilisaraji L, Michaud A, Grima A, Austin B, Douma R, Barbeau P, Butler C, et al. Evaluating comparative effectiveness of psychosocial interventions adjunctive to opioid agonist therapy for opioid use disorder: a systematic review with network meta-analyses. PLOS ONE. 2020;15:e0244401. doi:10.1371/journal.pone.0244401
   PubMed Web of Science ®Google Scholar
• Schwartz RP. When added to opioid agonist treatment, psychosocial interventions do not further reduce the use of illicit opioids: a comment on dugosh et al. J Addict Med. 2016;10:283–85. doi:10.1097/ADM.0000000000000236.
   PubMed Web of Science ®Google Scholar
• Hooker SA, Sherman MD, Lonergan-Cullum M, Sattler A, Liese BS, Justesen K, Nissly T, Levy R. Mental health and psychosocial needs of patients being treated for opioid use disorder in a primary care residency clinic. J Prim Care Community Health. 2020;11:2150132720932017. doi:10.1177/2150132720932017.
   Web of Science ®Google Scholar
• Andraka-Christou B, Randall-Kosich O, Totaram R. Designing an “Ideal” substance use disorder treatment center: perspectives of people who have utilized medications for opioid use disorder. Qual Health Res. 2021;31:512–22. doi:10.1177/1049732320971231.
   PubMed Web of Science ®Google Scholar
• Friedmann PD, Hendrickson JC, Gerstein DR, Zhang Z. The effect of matching comprehensive services to patients’ needs on drug use improvement in addiction treatment. Addiction. 2004;99:962–72. doi:10.1111/j.1360-0443.2004.00772.x.
   PubMed Web of Science ®Google Scholar
• Majer JM, Beasley C, Stecker E, Bobak TJ, Norris J, Nguyen HM, Ogata M, Siegel J, Isler B, Wiedbusch E, et al. Oxford house residents’ attitudes toward medication assisted treatment use in fellow residents. Community Ment Health J. 2018;54:571–77. doi:10.1007/s10597-017-0218-4
   PubMed Web of Science ®Google Scholar
• Majer JM, Jason LA, Norris J, Hickey P, Jeong H, Bobak TJ. Medications for opioid use disorder utilization among oxford house residents. Community Ment Health J. 2020;56:925–32. doi:10.1007/s10597-020-00558-y.
   PubMed Web of Science ®Google Scholar
• Stewart RE, Shen L, Kwon N, Vigderman J, Kramer S, Mandell DS, Candon M, Lamb R, Rothbard AB. Transporting to treatment: Evaluating the effectiveness of a mobile engagement unit. J Subst Abuse Treat. 2021;129:108377. doi:10.1016/j.jsat.2021.108377.
   PubMed Web of Science ®Google Scholar
• Stone R, Campbell JK, Kinney D, Rothman EF. “He would take my shoes and all the baby’s warm winter gear so we couldn’t leave”: barriers to safety and recovery experienced by a sample of vermont women with partner violence and opioid use disorder experiences. J Rural Health. 2021;37:35–44. doi:10.1111/jrh.12518.
   PubMed Web of Science ®Google Scholar
• Chatterjee A, Yu EJ, Tishberg L. Exploring opioid use disorder, its impact, and treatment among individuals experiencing homelessness as part of a family. Drug Alcohol Depen. 2018;188:161–68. doi:10.1016/j.drugalcdep.2018.04.012.
   PubMed Web of Science ®Google Scholar
• Tunney S. NJ MATrx Model. NJ Department Of Human Services, Division Of Medical Assistance And Health Services. 2019 Jan.
   Google Scholar
• National Association of State Alcohol and Drug Abuse Directors. New Jersey use of STR/SOR grant funds to address the opioid crisis. 2019.
   Google Scholar
• Hooker SA, Sherman MD, Lonergan-Cullum M, Nissly T, Levy R. What is success in treatment for opioid use disorder? Perspectives of physicians and patients in primary care settings. J Subst Abuse Treat. 2022;141:108804. doi:10.1016/j.jsat.2022.108804.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014:CD002207. doi:10.1002/14651858.CD002207.pub4.
   PubMed Web of Science ®Google Scholar
• Friedrichs A, Spies M, Härter M, Buchholz A, Fischer G. Patient preferences and shared decision making in the treatment of substance use disorders: a systematic review of the literature. PLoS One. 2016;11:e0145817. doi:10.1371/journal.pone.0145817.
   PubMed Web of Science ®Google Scholar
• Gertner AK, Robertson AG, Powell BJ, Jones H, Silberman P, Domino ME. Primary care providers and specialists deliver comparable buprenorphine treatment quality: study examines how buprenorphine treatment quality differed between primary care providers and specialists in North Carolina Medicaid. Health Aff. 2020;39:1395–404. doi:10.1377/hlthaff.2019.01559.
   Web of Science ®Google Scholar
• Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatry. 2015;23:63–75. doi:10.1097/HRP.0000000000000075.
   PubMed Web of Science ®Google Scholar
• Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, Ferri M, Pastor-Barriuso R. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550. doi:10.1136/bmj.j1550.
   PubMed Web of Science ®Google Scholar
• Samples H, Williams AR, Olfson M, Crystal S. Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees. J Subst Abuse Treat. 2018;95:9–17. doi:10.1016/j.jsat.2018.09.001.
   PubMed Web of Science ®Google Scholar
• Burgess A, Bauer E, Gallagher S, Karstens B, Lavoie L, Ahrens K, O’Connor A. Experiences of stigma among individuals in recovery from opioid use disorder in a rural setting: A qualitative analysis. J Subst Abuse Treat. 2021;130:108488. doi:10.1016/j.jsat.2021.108488.
   PubMed Web of Science ®Google Scholar
• Garett R, Young SD. The role of misinformation and stigma in opioid use disorder treatment uptake. Subst Use Misuse. 2022;57:1332–36. doi:10.1080/10826084.2022.2079133.
   PubMed Web of Science ®Google Scholar
• Ahern J, Stuber J, Galea S. Stigma, discrimination and the health of illicit drug users. Drug Alcohol Depen. 2007;88:188–96. doi:10.1016/j.drugalcdep.2006.10.014.
   PubMed Web of Science ®Google Scholar
• Kulesza M, Larimer ME, Rao D. Substance use related stigma: what we know and the way forward. J Addict Behav Ther Rehabil [Internet]. 2013;2. [accessed 2020 Oct 3]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4228689/.
   PubMedGoogle Scholar
• Cioe K, Biondi BE, Easly R, Simard A, Zheng X, Springer SA. A systematic review of patients’ and providers’ perspectives of medications for treatment of opioid use disorder. J Subst Abuse Treat. 2020;119:108146. doi:10.1016/j.jsat.2020.108146.
   PubMed Web of Science ®Google Scholar
• Brooks EM, Tong S. Implementing office-based opioid treatment models in primary care. J Am Board Fam Med. 2020;33:512–20. doi:10.3122/jabfm.2020.04.190240.
   PubMed Web of Science ®Google Scholar
• Kapadia SN, Griffin JL, Waldman J, Ziebarth NR, Schackman BR, Behrends CN. A harm reduction approach to treating opioid use disorder in an independent primary care practice: a qualitative study. J Gen Intern Med. 2021;36:1898–905. doi:10.1007/s11606-020-06409-6.
   PubMed Web of Science ®Google Scholar
• National Academy for State Health Policy. Medications for Opioid Use Disorder (MOUD) provided in State Prisons [Internet]. 2021 [accessed 2021 Sep 24]. https://www.nashp.org/nashp-chart-medications-for-opioid-use-disorder-provided-in-state-prisons-march-2021/.
   Google Scholar
• Sufrin C, Sutherland L, Beal L, Terplan M, Latkin C, Clarke JG. Opioid use disorder incidence and treatment among incarcerated pregnant women in the United States: results from a national surveillance study. Addiction. 2020;115:2057–65. doi:10.1111/add.15030.
   PubMed Web of Science ®Google Scholar
• Curtis M, Larney S, Higgs P, Cossar RD, Winter RJ, Stewart AC, Stoové M. Initiation of medications for opioid use disorder shortly before release from prison to promote treatment retention: strong evidence but compromised policy. J Addict Med [Internet]. 2021;15:525–26. https://journals.lww.com/journaladdictionmedicine/Fulltext/2021/12000/Initiation_of_Medications_for_Opioid_Use_Disorder.19.aspx.
   PubMed Web of Science ®Google Scholar
• Krans EE, Kim JY, Chen Q, Rothenberger SD, James AE III, Kelley D. Outcomes associated with the use of medications for opioid use disorder during pregnancy. Addiction. 2021;116:3504–14. doi:10.1111/add.15582.
   PubMed Web of Science ®Google Scholar
• Reuter QR, Santos AD, McKinnon J, Gothard D, Jouriles N, Seaberg D. Long-term treatment retention of an emergency department initiated medication for opioid use disorder program. Am J Emerg Med. 2022;55:98–102. doi:10.1016/j.ajem.2022.02.041.
   PubMed Web of Science ®Google Scholar
• Schoenfeld EM, Westafer LM, Beck SA, Potee BG, Vysetty S, Simon C, Tozloski JM, Girardin AL, Soares WE. “Just give them a choice”: patients’ perspectives on starting medications for opioid use disorder in the ED. Acad Emerg Med [Internet]. 29:928–43. [accessed 2022 May 25].
   PubMed Web of Science ®Google Scholar